PHAXIAM is a clinical-stage biopharmaceutical company developing innovative bacteriophage-based therapies to fight antimicrobial resistance (AMR).
PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, responsible for more than two-thirds of hospital-acquired resistant infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
PHAXIAM développe un portefeuille de phages ciblant 3 des bactéries les plus résistantes et les plus dangereuses, qui représentent à elles seules plus des deux tiers des infections nosocomiales résistantes : Staphylococcus aureus, Escherichia coli et Pseudomonas aeruginosa .
PHAXIAM is listed on the Nasdaq Capital Market in the United States (ticker: PHXM) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
PHAXIAM’s Audit Committee assists our board of directors in its oversight of our corporate accounting and financial reporting and submits the selection of our statutory auditors, their remuneration and independence for approval. It is composed of Hilde Windels, Philippe Archinard and Eric Leire for the Board of Directors and Eric Soyer and Thibaut du Fayet who represent PHAXIAM’s management team.
Our clinical strategy committee is responsible for analyzing and reviewing our clinical and regulatory strategy. It meets, at least once a year, and makes recommendations to PHAXIAM’s Board of Directors regarding our clinical and regulatory development strategy.
PHAXIAM’s clinical strategy committee is composed of Martine George, Philippe Archinard and Robert Sebbag for the Board of Directors and Pascal Birman, Frédérique Vieville and Thibaut du Fayet who represent PHAXIAM’s management team.
The Remuneration and Appointments Committee hears the directors’ assessments of PHAXIAM’s performance against defined objectives. It meets at least once a year, without the directors being present, to assess their individual performance and, after conferring with them, makes recommendations to the Board of Directors concerning their remuneration.
It is composed of Philippe Archinard, Leïla Nicolas et Hilde Windels for the Board of Directors, and Eric Soyer, Chief Financiel Officer, Chief Operating Officer and Deputy General Manager of PHAXIAM.
.png)
Please note that any opinions, estimates or forecasts regarding ERYTECH Pharma performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of ERYTECH Pharma or its management. ERYTECH Pharma does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
Would you like to subscribe to our alerts to receive all our investor information directly in your mailbox? Please enter your email address in the field below and select the type of information you are interested in.
We respect your privacy and will not share your data with third parties. You can unsubscribe at any time from alerts to which you have subscribed.
For more information on our data protection policy, please consult our privacy policy.
To contact our investor relations team
Eric Soyer
CFO, COO and Deputy General Manager
+33(0)4 78 74 44 38
investors@phaxiam.com
Mathilde Bohin / Dusan Oresansky
+33(0)1 44 71 94 94
phaxiam@newcap.eu
Arthur Rouillé
+33(0)1 44 71 94 94
phaxiam@newcap.eu
